In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...

Ironwood Pharmaceuticals has been left considering its options after the FDA demanded another phase 3 trial before it will ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

A study led by two undergraduate students at the University of Galway found that GLP-1 receptor agonists, a type of diabetes ...

The study supports prior research that found the same thing.

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...